fbpx
ACRF Accelerate

ACRF ACCELERATE REFERENCES 

ACRF Lung Cancer Screening Centre of Excellence (LUSCE)

  1. Australian Institute of Health and Welfare. Cancer data in Australia. 2021; Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-summary-data-visualisation.
  2. Aberle, D.R., et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011. 365(5): p. 395-409.
  3. de Koning, H.J., et al., Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med, 2020. 382(6): p. 503-513.
  4. Sadate, A., et al., Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography. Eur J Cancer, 2020. 134: p. 107-114.
  5. Australian Institute of Health and Welfare, Rural & remote health.
  6. Australian Institute of Health and Welfare, Cancer in Aboriginal & Torres Strait Islander people of Australia. 2018.
  7. Cancer Australia, Report on the Lung Cancer Screening Enquiry. 2020.
  8. Goldsbury, D.E., et al., Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. PLoS One, 2018. 13(7): p. e0201552.
  9. Goldsbury, D.E., et al., Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study. PLoS One, 2020. 15(8): p. e0238018.
  10. Lung Foundation Australia, Making Lung Cancer A Fair Fight: A Blueprint for Reform. 2018.
  11. Mazanec, S.R., et al., Work productivity and health of informal caregivers of persons with advanced cancer. Res Nurs Health, 2011. 34(6): p. 483-95.
  12. Pearce, A., et al., Projecting productivity losses for cancer-related mortality 2011 – 2030. BMC Cancer, 2016. 16(1): p. 804.
  13. The Australian Society of Medical Research, Economic Impact of Medical Research in Australia. 2018.
  14. Deloitte Access Economics, Australia’s health and medical research workforce. 2016.
  15. The Australian Society of Medical Research, Economic Impact of Medical Research in Australia. 2018.
  16. Deloitte Access Economics, Australia’s health and medical research workforce. 2016.

ACRF Centre for Intravital Imaging of Niches for Cancer

  1. Australian Institute of Health and Welfare, Cancer in Australia, in Cancer series no. 119. Cat. no. CAN. 123. 2019: Canberra: AIHW.
  2. Carbone, D.P., et al., Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. Journal of Thoracic Oncology, 2015. 10(7): p. 974-984.
  3. Goldsbury, D.E., et al., Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. PLOS ONE, 2018. 13(7): p. e0201552.
  4. Mazanec, S.R., et al., Work productivity and health of informal caregivers of persons with advanced cancer. Research in nursing & health, 2011. 34(6): p. 483-495.
  5. The Australian Society for Medical Research, Australia’s health and medical research workforce. Expert people providing exceptional returns. 2016, Deloitte Access Economics.
  6. The Australian Society for Medical Research, Australia’s health and medical research workforce. Expert people providing exceptional returns. 2016, Deloitte Access Economics.

 ACRF Molecular Theranostics Laboratory

  1. Australian Institue of Health and Welfare. Cancer data in Australia. 2021; Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-summary-data-visualisation.
  2. Sumer, B. and J. Gao, Theranostic nanomedicine for cancer. Nanomedicine (Lond), 2008. 3(2): p. 137-40.
  3. Fendler, W.P., et al., Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol, 2019. 5(6): p. 856-863.
  4. Hofman, M.S., et al., [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet, 2021. 397(10276): p. 797-804.
  5. Pinter, M., et al., Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open, 2016. 1(2): p. e000042.
  6. Chen, M., et al., Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. J Clin Invest, 2017. 127(10): p. 3689-3701.
  7. Douglass, A., et al., Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol, 2008. 49(1): p. 88-98.
  8. Alberti, A., L. Chemello, and L. Benvegnù, Natural history of hepatitis C. J Hepatol, 1999. 31 Suppl 1: p. 17-24.
  9. Forner, A., J.M. Llovet, and J. Bruix, Hepatocellular carcinoma. Lancet, 2012. 379(9822): p. 1245-55.
  10. Polaris Observatory HCV Collaborators, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol, 2017. 2(3): p. 161-176.
  11. Goldsbury, D.E., et al., Health services costs for cancer care in Australia: Estimates from the 45 and Up Study. PLoS One, 2018. 13(7): p. e0201552.
  12. Mazanec, S.R., et al., Work productivity and health of informal caregivers of persons with advanced cancer. Res Nurs Health, 2011. 34(6): p. 483-95.
  13. Pearce, A., et al., Projecting productivity losses for cancer-related mortality 2011 – 2030. BMC Cancer, 2016. 16(1): p. 804.
  14. The Australian Society of Medical Research, Economic Impact of Medical Research in Australia. 2018.
  15. Deloitte Access Economics, Australia’s health and medical research workforce. 2016.

ACRF International Centre for Cancer Glycomics

  1. Reily, 1. Reily, C., et al., Glycosylation in health and disease. Nat Rev Nephrol, 2019. 15(6): p. 346-366.
  2. Hegde, P.S. and D.S. Chen, Top 10 Challenges in Cancer Immunotherapy. Immunity, 2020. 52(1): p. 17-35.
  3. Barrueto, L., et al., Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Transl Oncol, 2020. 13(3): p. 100738.
  4. Lu, R.M., et al., Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci, 2020. 27(1): p. 1.
  5. Australian Institute of Health and Welfare. Cancer data in Australia. 2021; Available from: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-summary-data-visualisation.
  6. Australian Institute of Health and Welfare, Cancer in Australia 2019. 2019.
  7. eviQ. Medical Oncology. 2021; Available from: https://www.eviq.org.au/medical-oncology.
  8. Australian Institute of Health and Welfare, Cancer mortality trends and projections: 2014 to 2025. 2015.
  9. Australian Instutite of Health and Welfare, Cancer in Australia 2017. 2017.
  10. Deloitte Access Economics, The New Wave of Immunotherapy Cancer Medicines- The Untapped Potential for Australians. 2017.
  11. Gedye, C., Cancer immunotherapy drugs like Keytruda and Opdivo hold hope for some, but there’s still a way to go. 2017.
  12. Cancer Australia, 5-year relative survival. 2020.
  13. Cancer Council NSW. Staging and prognosis for ovarian cancer. 2021; Available from: https://www.cancercouncil.com.au/ovarian-cancer/diagnosis/staging-prognosis/.
  14. Metcalfe, K.A., et al., The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol, 2005. 96(1): p. 222-6.
  15. Mazanec, S.R., et al., Work productivity and health of informal caregivers of persons with advanced cancer. Res Nurs Health, 2011. 34(6): p. 483-95.
  16. Pearce, A., et al., Projecting productivity losses for cancer-related mortality 2011 – 2030. BMC Cancer, 2016. 16(1): p. 804.
  17. Haslem, D.S., et al., A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. J Oncol Pract, 2017. 13(2): p. e108-e119.
  18. The Australian Society of Medical Research, Economic Impact of Medical Research in Australia. 2018.
  19. Mlinarić, A., M. Horvat, and V. Šupak Smolčić, Dealing with the positive publication bias: Why you should really publish your negative results. Biochem Med (Zagreb), 2017. 27(3): p. 030201.
  20. Deloitte Access Economics, Australia’s health and medical research workforce. 2016.